Objective:To investigate the influence of integrated traditional Chinese and Western medicine on the related indexes and TCM syndrome scores of patients with non-alcoholic fatty liver disease.Methods: A total of 128 p...Objective:To investigate the influence of integrated traditional Chinese and Western medicine on the related indexes and TCM syndrome scores of patients with non-alcoholic fatty liver disease.Methods: A total of 128 patients with non-alcoholic fatty liver disease who were admitted to our department from January 2017 to May 18, 2017 were enrolled in the study. According to the hospital admission record number, they were randomly divided into treatment groups (64 cases). and the control group (64 cases). The control group was treated with rosuvastatin calcium tablets. The treatment group was treated with Jiangzhi Fanggan Recipe on the basis of the control group. The treatment was performed for 10 d for a total of 3 courses. Comparison of liver function, blood lipids, insulin resistance index (HOMA-IR), iris (Irisin), superoxide dismutase (SOD), malondialdehyde (MDA), body mass index (BMI), waist circumference (WC), Liver/spleen CT ratio and TCM syndrome scores.Results: The curative effect of TCM symptom in the treatment group (82.82%) was significantly higher than that in the control group (65.62%), and the difference was statistically significant. There was no difference between the two groups before treatment. Compared with before treatment, the levels of each index were significantly improved after treatment, and the improvement of the treatment group was more significant than that of the control group.Conclusion: The combination of traditional Chinese and Western medicine can improve the symptoms of patients, achieve good clinical efficacy, and have certain anti-oxidative stress effects, which is worthy of clinical promotion or further research.展开更多
BACKGROUND:Sepsis is a common cause of death in emergency departments and sepsis-associated encephalopathy(SAE)is a major complication.Rosuvastatin may play a neuroprotective role due to its protective effects on the ...BACKGROUND:Sepsis is a common cause of death in emergency departments and sepsis-associated encephalopathy(SAE)is a major complication.Rosuvastatin may play a neuroprotective role due to its protective effects on the vascular endothelium and its anti-inflammatory functions.Our study aimed to explore the potential protective function of rosuvastatin against SAE.METHODS:Sepsis patients without any neurological dysfunction on admission were prospectively enrolled in the“Rosuvastatin for Sepsis-Associated Acute Respiratory Distress Syndrome”study(SAILS trial,ClinicalTrials.gov number:NCT00979121).Patients were divided into rosuvastatin and placebo groups.This is a secondary analysis of the SAILS dataset.Baseline characteristics,therapy outcomes,and adverse drug events were compared between groups.RESULTS:A total of 86 patients were eligible for our study.Of these patients,51 were treated with rosuvastatin.There were significantly fewer cases of SAE in the rosuvastatin group than in the placebo group(32.1%vs.57.1%,P=0.028).However,creatine kinase levels were significantly higher in the rosuvastatin group than in the placebo group(233[22-689]U/L vs.79[12-206]U/L,P=0.034).CONCLUSION:Rosuvastatin appears to have a protective role against SAE but may result in a higher incidence of adverse events.展开更多
文摘Objective:To investigate the influence of integrated traditional Chinese and Western medicine on the related indexes and TCM syndrome scores of patients with non-alcoholic fatty liver disease.Methods: A total of 128 patients with non-alcoholic fatty liver disease who were admitted to our department from January 2017 to May 18, 2017 were enrolled in the study. According to the hospital admission record number, they were randomly divided into treatment groups (64 cases). and the control group (64 cases). The control group was treated with rosuvastatin calcium tablets. The treatment group was treated with Jiangzhi Fanggan Recipe on the basis of the control group. The treatment was performed for 10 d for a total of 3 courses. Comparison of liver function, blood lipids, insulin resistance index (HOMA-IR), iris (Irisin), superoxide dismutase (SOD), malondialdehyde (MDA), body mass index (BMI), waist circumference (WC), Liver/spleen CT ratio and TCM syndrome scores.Results: The curative effect of TCM symptom in the treatment group (82.82%) was significantly higher than that in the control group (65.62%), and the difference was statistically significant. There was no difference between the two groups before treatment. Compared with before treatment, the levels of each index were significantly improved after treatment, and the improvement of the treatment group was more significant than that of the control group.Conclusion: The combination of traditional Chinese and Western medicine can improve the symptoms of patients, achieve good clinical efficacy, and have certain anti-oxidative stress effects, which is worthy of clinical promotion or further research.
基金This research received funding from the CAMS Innovation Fund for Medical Sciences(CIFMS)(2020-I2M-C&T-B-014,2021-I2M-1-020).
文摘BACKGROUND:Sepsis is a common cause of death in emergency departments and sepsis-associated encephalopathy(SAE)is a major complication.Rosuvastatin may play a neuroprotective role due to its protective effects on the vascular endothelium and its anti-inflammatory functions.Our study aimed to explore the potential protective function of rosuvastatin against SAE.METHODS:Sepsis patients without any neurological dysfunction on admission were prospectively enrolled in the“Rosuvastatin for Sepsis-Associated Acute Respiratory Distress Syndrome”study(SAILS trial,ClinicalTrials.gov number:NCT00979121).Patients were divided into rosuvastatin and placebo groups.This is a secondary analysis of the SAILS dataset.Baseline characteristics,therapy outcomes,and adverse drug events were compared between groups.RESULTS:A total of 86 patients were eligible for our study.Of these patients,51 were treated with rosuvastatin.There were significantly fewer cases of SAE in the rosuvastatin group than in the placebo group(32.1%vs.57.1%,P=0.028).However,creatine kinase levels were significantly higher in the rosuvastatin group than in the placebo group(233[22-689]U/L vs.79[12-206]U/L,P=0.034).CONCLUSION:Rosuvastatin appears to have a protective role against SAE but may result in a higher incidence of adverse events.
